公开(公告)号：AU2004251136B2

公开(公告)日：2009-05-07

申请号：AU2004251136

申请日：2004-05-13

Applicant: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY

Inventor： YUSHAK MELINDA L ,  TSANG VICTOR C W ,  HANCOCK KATHY ,  PATTABHI SOWMYA ,  WILLIAMS FATIMA

IPC: A61K38/00 ,  A61K39/00 ,  C07K14/435

Abstract: The present disclosure relates to T24 nucleic acid sequences, amino acid sequences, and antibodies. Methods for detecting and diagnosing Taenia solium infection in a subject using the T24 sequences and specific binding agents are also disclosed. The T24 sequences disclosed herein can be formulated into a pharmaceutical composition for administration to a subject. For example, the disclosed T24 polypeptides can also be administered to a subject to stimulate an immune response in the subject, thereby protecting the subject against T. solium infection.

公开(公告)号：AU2002353822B2

公开(公告)日：2008-11-06

申请号：AU2002353822

申请日：2002-10-15

Applicant: THE GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVIC

Inventor： LIU KE ,  ROSENBERG STEVEN A

IPC: A61K35/14 ,  A61K35/17 ,  A61K38/20 ,  A61K39/00 ,  C07H21/02 ,  C07H21/04 ,  C12N5/0783

公开(公告)号：AU2003216111C1

公开(公告)日：2008-08-21

申请号：AU2003216111

申请日：2003-01-23

Applicant: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY ,  UNIV UTAH RES FOUND

Inventor： WU YUAN YUAN ,  MUJTABA TAHMINA ,  LIU YING ,  RAO MAHENDRA S

IPC: A61K35/12 ,  C12N5/0797

Abstract: An isolated, pure homogeneous population of mammalian astrocyte restricted precursor cells which is CD44 immunoreactive and which generate astrocytes but not oligodendrocytes is provided. Methods for identifying, isolating and using these mammalian astrocyte restricted precursor cells are also provided.

公开(公告)号：AU2008203034A1

公开(公告)日：2008-07-31

申请号：AU2008203034

申请日：2008-07-09

Applicant: THE GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SER

Inventor： BUKREYEV ALEXANDER A ,  WHITEHEAD STEPHEN S ,  TENG MICHAEL N ,  MURPHY BRIAN R ,  JUHASZ KATALIN ,  COLLINS PETER L

IPC: C12N7/04 ,  A61K39/155 ,  C12N7/01 ,  C12N15/45

公开(公告)号：AU2002352913B2

公开(公告)日：2008-05-29

申请号：AU2002352913

申请日：2002-11-26

Applicant: THE GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY

Inventor： TSANG KWONG-YOK ,  SCHLOM JEFFREY

IPC: G01N33/50 ,  A61K31/7088 ,  A61K35/12 ,  A61K35/14 ,  A61K35/76 ,  A61K38/00 ,  A61K38/21 ,  A61K39/39 ,  A61K48/00 ,  A61P13/08 ,  A61P35/00 ,  C07K7/06 ,  C07K14/47 ,  C07K16/18 ,  C12N5/08 ,  C12N5/10 ,  C12N9/64 ,  C12N15/09 ,  C12P21/02 ,  C12P21/08 ,  C12Q1/02 ,  C12Q1/68 ,  G01N33/15 ,  G01N33/53 ,  G01N33/566

Abstract: This invention relates to isolated peptides comprising agonist epitopes of prostate-specific antigen (PSA). In various aspects, the invention relates to peptides comprising agonist epitopes of the PSA-3 cytotoxic T lymphocyte epitope, and nucleic acids encoding peptides that comprise PSA-3 agonist epitopes. Also related are probes, primers, and vectors comprising these nucleic acids, as well as host cells comprising these vectors, and antibodies that bind to the PSA-3 agonist peptides. This invention further relates to diagnostic reagents and methods utilizing the disclosed nucleic acids or antibodies. The invention also relates to pharmaceutical compositions comprising the nucleic acids, host cells, and peptides of the invention, as well as methods of treatment or prevention of prostate cancer employing such compositions, for example, for peptide-mediated, cell-mediated, and vector-mediated immunotherapies.

公开(公告)号：AU2004205289B2

公开(公告)日：2008-04-17

申请号：AU2004205289

申请日：2004-08-27

Applicant: THE GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SER

Inventor： MURPHY BRIAN R ,  WHITEHEAD STEPHEN S ,  JUHASZ KATALIN ,  COLLINS PETER L ,  BUKREYEV ALEXANDER A ,  TENG MICHAEL N

IPC: C12N7/04 ,  A61K39/155 ,  C12N7/01 ,  C12N15/45

公开(公告)号：AU2002211948B2

公开(公告)日：2007-09-13

申请号：AU2002211948

申请日：2001-03-02

Applicant: UNIV EMORY ,  THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY

Inventor： WYATT LINDA S ,  SMITH JAMES M ,  ELLENBERGER DENNIS ,  EARL PATRICIA L ,  BUTERA SALVATORE T ,  HUA JIAN ,  BRIGHT RICK ARTHUR ,  ROBINSON HARRIET L ,  MOSS BERNARD ,  FOLKS THOMAS M ,  ROSS TED M ,  AMARA RAMA R

IPC: C12N15/09 ,  A61K35/76 ,  A61K39/00 ,  A61K39/145 ,  A61K39/165 ,  A61K39/21 ,  A61K48/00 ,  C07K14/16 ,  C07K14/47 ,  C07K16/10 ,  C12N15/63 ,  C12N15/67 ,  C12N15/70 ,  C12N15/85

Abstract: The present invention provides novel pGA constructs which are useful as vectors for the delivery of DNA vaccine inserts. The vaccine inserts can include the DNA transcripts of various virus, bacteria, parasite and/or fungi. Also described are methods of raising multi-epitope CD8 T-cell responses by administering therapeutically effective amounts of the novel pGA constructs comprising pathogen vaccine inserts followed by booster immunizations with a live vectored vaccine comprising the same vaccine inserts.

公开(公告)号：AU2002307020B2

公开(公告)日：2007-06-28

申请号：AU2002307020

申请日：2002-03-28

Applicant: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY

Inventor： SAUSVILLE EDWARD A ,  SNADER KENNETH M ,  HOLLINGSHEAD MELINDA G ,  VISHNUVAJJALA B RAO

IPC: C07D225/06 ,  A61K31/395 ,  A61P35/00 ,  A61P43/00

Abstract: A geldanamycin derivative exhibiting significant preliminary in vivo activity, particularly significant oral in vivo activity, and a method of treating or preventing cancer in a host comprising administering a geldanamycin derivative to a host in an amount sufficient to treat or prevent cancer.

公开(公告)号：AU2006252238A1

公开(公告)日：2007-01-25

申请号：AU2006252238

申请日：2006-12-22

Applicant: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN

Inventor： MURPHY BRIAN R ,  WHITEHEAD STEPHEN S ,  KREMPL CHRISTINE D ,  COLLINS PETER L ,  BUCHHOLZ URSULA

IPC: C12N15/09 ,  A61K39/12 ,  A61K39/155 ,  A61P31/14 ,  C12N7/00 ,  C12N7/02 ,  C12N7/04

Abstract: Recombinant respiratory syncytial virus (RSV) having the position of genes shifted within the genome or antigenome of the recombinant virus are infectious and attenuated in humans and other mammals. Gene shifted RSV are constructed by insertion, deletion or rearrangement of genes or genome segments within the recombinant genome or antigenome and are useful in vaccine formulations for eliciting an anti-RSV immune response. Also provided are isolated polynucleotide molecules and vectors incorporating a recombinant RSV genome or antigenome wherein a gene or gene segment is shifted to a more promoter-proximal or promoter-distal position within the genome or antigenome compared to a wild type position of the gene in the RSV gene map. Shifting the position of genes in this manner provides for a selected increase or decrease in expression of the gene, depending on the nature and degree of the positional shift. In one embodiment, RSV glycoproteins are upregulated by shifting one or more glycoprotein-encoding genes to a more promoter-proximal position. Genes of interest for manipulation to create gene position-shifted RSV include any of the NS1, NS2, N, P, M, SH, M2(ORF1), M2(ORF2), L, F or G genes or a genome segment that may be part of a gene or extragenic. A variety of additional mutations and nucleotide modifications are provided within the gene position-shifted RSV of the invention to yield desired phenotypic and structural effects.

公开(公告)号：AU2006251893A1

公开(公告)日：2006-11-30

申请号：AU2006251893

申请日：2006-05-18

Applicant: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH

Inventor： FUREY MAURA L ,  DREVETS WAYNE C

IPC: A61K31/46 ,  A61K9/12 ,  A61P25/22 ,  A61P25/24